LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Thera… Read more
LENZ Therapeutics Inc (LENZ) - Total Assets
Latest total assets as of September 2025: $210.70 Million USD
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) holds total assets worth $210.70 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LENZ Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how LENZ Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
LENZ Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
LENZ Therapeutics Inc's total assets of $210.70 Million consist of 98.4% current assets and 1.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how LENZ Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LENZ Therapeutics Inc's current assets represent 98.4% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, down from 100.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
LENZ Therapeutics Inc Competitors by Total Assets
Key competitors of LENZ Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
LENZ Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - LENZ Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - LENZ Therapeutics Inc is currently not profitable relative to its asset base.
LENZ Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.69 | 28.63 | 0.66 |
| Quick Ratio | 12.63 | 28.63 | 0.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $190.68 Million | $ 212.99 Million | $ -10.95 Million |
LENZ Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between LENZ Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 1.09 |
| Asset Growth Rate (YoY) | 205.9% |
| Total Assets | $215.30 Million |
| Market Capitalization | $235.01 Million USD |
Valuation Analysis
Above Book Valuation: The market values LENZ Therapeutics Inc's assets above their book value (1.09 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: LENZ Therapeutics Inc's assets grew by 205.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for LENZ Therapeutics Inc (2019–2024)
The table below shows the annual total assets of LENZ Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $215.30 Million | +205.93% |
| 2023-12-31 | $70.38 Million | +49.89% |
| 2022-12-31 | $46.95 Million | +156.07% |
| 2021-12-31 | $18.34 Million | -18.74% |
| 2020-12-31 | $22.56 Million | +375966.67% |
| 2019-12-31 | $6.00K | -- |